Importantly, clinical trials have suggested the potential benefits of SGLT2 inhibitors as an adjunctive treatment for type 1 diabetes (T1D) [30], especially in combination with insulin therapy to improve glycemic control in patients with inadequately controlled TID [31]. The gene discussed is INS; the disease is type 1 diabetes mellitus.